Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting

– STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO₂ as the primary endpoint –

– STRATUS-HCM on track to start in the fourth quarter of 2026 –